(INR) (3) . In patients with atrial fibrillation the risk of stroke rises steeply with INR values below 1.8 (4) and INRs greater than 4 to 5 rapidly increase the bleeding rate (5) (6) . A recently published epidemiological study with 1.25 million INR values from more than 40 000 oral anticoagulation patients has shown that the risk of bleeding was lowest at an INR of 2.2-2.3 and higher levels of INR led to a continuously increased risk of bleeding (7) .
The management of anticoagulation is often monitored by specialised anticoagulation clinics or general practitioners. As early as 1974, doctors started to offer their patients instruction in oral anticoagulation treatment (8) , and in the 1980s, home monitoring devices were introduced to allow patients to monitor their anticoagulation status themselves (9) . When trained by a qualified person to use the home monitor, instructed on how to perform dose adjustments, manage their diets, and what to do under special circumstances such as surgery or drug interactions, patients started to self-manage their oral anticoagulation treatment (10, 11) . In this context, it is important to differentiate between sole INR self-testing, and full self-management. Selfmanagement includes self-adaptation of the anticoagulation treatment based on self-monitoring results after participation in a structured teaching and treatment programme. Previously published papers have shown that the anticoagulation status of self-managed patients is better than (11) (12) (13) (14) (15) (16) , or at least equivalent (17) , to that of patients monitored by a specialised anticoagulation clinic or general practitioner.
The aim of our study was to perform a systematic review of controlled and randomised trials, comparing self-managed patients to patients under routine care provided by general practitioners or special haemostasis care units. Our goal was to evaluate the improvement of therapeutic control of anticoagulation, the possible reduction of major bleedings, arterial or venous thromboembolism and the improvement in treatment-related quality of life.
Materials and methods

Inclusion criteria
Only randomised controlled trials were considered, involving patients with oral anticoagulation (irrespective of indication for oral anticoagulation) of any age or sex, which were designed to compare a self-management group to a routine care group. The participants in the self-management group performed measurements and dosage adjustments by themselves.
Outcome measures
We extracted information on the following outcome measures: anticoagulation control (such as the number of INRs in the therapeutic range, squared INR deviation from the therapeutic target), major bleedings (such as life-threatening bleeding, severe bleeding requiring transfusion or intracranial bleeding and major bleedings according to the Landefeld criteria (18)), recurrent thromboembolism (arterial and venous such as stroke, myocardial infarction, deep venous thrombosis, pulmonary embolism) and treatment-related quality of life measurements according to a questionnaire that was validated in the study of Sawicki et al. (13) . This questionnaire covers patients' feelings about oral anticoagulation, general treatment satisfaction, selfefficacy, strained social network, daily hassles and distress (13, 19) .
Search strategy for identification of studies
Published studies were identified with a literature search using the COCHRANE LIBRARY, MEDLINE, EMBASE and the Cochrane Controlled Trials Register (CCTR) from 1966 to January 2003. We used the standard searches provided by the Cochrane Metabolic and Endocrine Disorders Group (20) and the search terms for randomised controlled trials AND "oral anticoagulation" or "anticoagulation agent or drug" or "thromboembolism drug or agent or therapy" or "vitamin K antagonist" or "coumarin*" or "anticoagulant*" or "anti-coagulant*" or "phenprocoumon" or "warfarin" or "acenocoumarol" AND "self medication" or "home monitoring" or "education*" or "education program" or "self evaluation" or "self care" or "patient education". No language restriction was applied. The electronic searches were carried out by the reviewers. Only full papers were included for the systematic review, and additional searching used cross-references from original articles and reviews. Furthermore, authors, experts in this field and Roche Diagnostics in Vienna were queried as to further published literature.
Study selection and quality assessment
One reviewer screened the title, abstract and keywords of each reference identified by the search and applied the inclusion criteria (randomised controlled trial, self-management control versus routine care in oral anticoagulation patients; outcomes; anticoagulation control, major bleeding, recurrent thromboembolism, all-cause mortality and treatment-related quality of life). Methodological quality was assessed by two independent reviewers, using a modification of the criteria given in the Cochrane Handbook, and the criteria of Jadad (21) and Schulz (22) . We used three categories: assessment A: plausible bias is unlikely to seriously affect the results; assessment B: plausible bias raises some doubts about the results; and assessment C: plausible bias seriously weakens confidence in the results. In the case of the ref. 13 A. S. and A. B assessed the methodological quality.
Results
We identified nine potentially relevant randomised controlled trials, which had been published by January 2003. Two further studies were excluded because of double publication (14) (15) . In addition, two studies had to be excluded, because the oral anticoagulation patients had only self-tested themselves, but not self-managed their treatment (9, 23) . Five studies (12-13, 16, 17, 24) remained, which fulfilled the criteria for inclusion. One study, however, was only published as an abstract , which meant that quality assessment was not possible (24) . Ultimately, four studies (12-13, 16, 17) were included in the systematic review.
Characteristics of the trials
The study by Cromheecke et al. (17) consisted of 50 patients in a cross-over design in which patients on life-long anticoagulation were treated with phenprocoumon or acencoumarol. The mean follow-up was 3 months. In the second paper, published by Sawicki et al. (13) , 179 orally anticoagulated patients were on life-long treatment with phenprocoumon. The mean followup was 6 months. The third paper, Watzke et al. (12) , covered 113 patients, who were only included if more than 50% of all INRs were within the therapeutic range in the previous 6 months. The patients were treated with phenprocoumon and the mean follow-up was 6 months. The fourth study, Koertke et al. (16) has been published three times in very similar versions. After heart valve replacement, 1200 patients were randomised and followed up for 24 months. The main characteristics of these trials are given in Table 1 .
All four studies were evaluated, and the results of the studies by Cromheecke, Sawicki and Watzke (12) (13) 17) raised no serious doubts about the results obtained. The quality of the study by Koertke (16) was assessed as category C, because the reviewers decided that it was undoubtedly biased: it was presented in three different publications (14-16) with diverging numbers of events and deaths, and an extraordinarily high number of patients, who were lost to follow-up (Table 1 ). Therefore, for a possible statistical analysis after exclusion of Koertke's study, three studies remained. However, due to clinical and methodological heterogeneity of the three remaining studies no formal analysis (combination of the results) was possible. The differences of the four studies are summarized in table 1.
Anticoagulation control
After contacting the corresponding author (Prof. Levi) for the study by Cromheecke et al. (17) , data on absolute numbers for (17) , whose patients were self-managed or in the control group managed by the specialised anticoagulation clinic for a period of 3 months, gained no significant difference in the overall quality of control of anticoagulation between the two study periods (p=0.06). Sawicki (13) compared the self-management group with a control group who received care from general practitioners. The deviation of the INR value from the mean of the INR target range was shown to be significantly lower in the intervention group at the 3 month (p<0.001) and 6 month follow-up (p=0.03). The intervention group also had INR values more often within the target range (repeated measurements analysis for categorical data, p=0.006). Watzke (12) showed that patients on self-management had more INR values within the therapeutic range than patients on routine care treatment supervised by general practitioners (84.5% versus 73.8%). In addition, the mean square deviation was considerably lower in the patients on self-management when compared to routine care (0.32 ± 0.18 vs. 0.58 ± 0.4). Koertke's study (16) again confirmed the superiority of self-management, with 79.2% of INR values within the therapeutic target range compared to 64.9% for the control group supervised by general practitioners (p<0.001).
Major bleedings
Absolute numbers of major bleeding events were available for all four studies (Table 3) . With the exception of Koertke et al. (16) , they were underpowered due to the small numbers of patients and the short observation periods. In this study there was no difference in major bleeding; however, these results are not likely to be valid because of the poor quality of the study (Table 1) .
Thromboembolism
Data on arterial and venous thromboembolism were available for all four studies (Table 3) . However, statistical analysis was not possible, because the studies by Cromheecke, Sawicki and Watzke (12) (13) 17) did not use thromboembolism as a primary endpoint, and a meta-analysis cannot be performed with one single study (16) . This study demonstrated a significant reduction in major thromboembolism in the intervention group (p=0.026) after following his subjects for two years.
Treatment-related quality of life Data were available for two studies (13, 17) both of which used the same quality of life questionnaire. The internal reliability of both studies was acceptable as indicated by the Cronbach-α values (19) . There were significant differences in all five categories of the questionnaire in favour of the self-management group in Cromheecke et al. In Sawicki et al., all scores (except strained social network) also improved significantly in the self-management group.
Discussion
This systematic review attempted to answer clinically relevant questions by assessing evidence on self-management of oral anticoagulation. As most of the studies including patients on a self-management programme were uncontrolled and retrospective, only four randomised controlled trials could be included in the systematic review. A formal meta-analysis was not possible, as after exclusion of one low quality trial (16) , three studies with clinical and methodological heterogeneity remained: Watzke used different inclusion criteria with only a highly selected patient group, in Cromheecke's study patients' supervision in the control group differed substantially from the other control groups (specialised anticoagulation clinic) and Sawicki provided only 2 centrally measured INR values compared to an average of 46 self measured records in Watzke's intervention group (personal communication). In the case of major bleeding or arterial or venous thromboembolism, all the studies were either too small, had too short an observation period (12) (13) 17) or the study quality was low (16) .
Looking at oral anticoagulation control, INR self-management is at least equivalent to management by a specialised anticoagulation clinic (17) and seems to offer more accurate control than routine care supervised by general practitioners (12-13). Koertke et al. (16) , with the extraordinarily large number of patients who were lost to follow-up, also underlined the superiority of self-managed patients. Patients had several hours of training in self-management in all the studies and the training programme was well described in all the studies, except Koertke et al. (Table 1) . Furthermore, there is good evidence from cohort studies performed by Ansell et al. (11) and retrospective studies (25) , that oral anticoagulation self-management is indeed superior to routine care with regard to risk reduction of over-and under-anticoagulation
In terms of major bleeding complications, there was only the study of Koertke (16) with enough patients to allow a difference between intervention and control groups to be detected but the results showed no difference between the two groups. The same randomised controlled trial has so far demonstrated a decrease in recurrent thromboembolism (16) under self-management. In this study (quality assessment C) involving patients after heart valve replacement, the risk of major thromboembolism was significantly reduced after a two-year follow-up period.
Two studies have convincingly shown that the quality of life of patients who managed oral anticoagulation themselves had significantly improved (13, 17) . This positive change was confirmed by another prospective study on a cohort of 100 patients under self-managed oral anticoagulation (26) , who were followed for a period of 6 months.
Long-term data on patients performing self-management are very rare. However, there is a non-randomised five-year study showing, for the first time, a long-term benefit from participation in a structured teaching and treatment programme (27) . After finishing the 6-month controlled study (13) , in which patients were randomised into self-management or routine management groups, Sawicki et al. performed a follow-up study. The structured instructional programme was also offered to the routine care group. During the 5-year follow-up period, 62% of INR self-measurements were within the target range, the bleeding risk was only 0.62 per 100 patient years (py), and thromboembolic events occurred only in 1.1 per 100 py. This indicates an enormous improvement in patients' related risks, especially compared to bleeding rates as high as 2.7 per 100 py in patients with mechanical heart valves (28), or 6.0 per 100 py in a Danish population-based cohort (29) .
It would also be interesting to know, how a self-management programme benefits different age groups. In children, oral anticoagulation treatment requires more frequent monitoring than in adults, because of the complexity and labile nature of paediatric diseases requiring anticoagulation. Home monitors can be advantageous for oral anticoagulation management, and reduce the need for venous blood collection. There is some evidence that oral anticoagulation self-testing (30, 31) and management (32) is safe for children, if they and their parents are suitably trained, although this is not yet backed up by randomised controlled studies.
In the elderly, the thromboembolic event rate increases rapidly with age (33) , and the bleeding risk is doubled in those over 70 years of age (34) . Both can be reduced when the elderly receive oral anticoagulation (33) , based on regularly monitored INR values (23) . To date only the prospective study by Beyth et al. (23) has shown that, excessive bleeding rates can be successfully reduced when elderly patients perform self-testing.
There is, however, an ongoing two-year follow-up study examining elderly patients with long term anticoagulation treatment, and randomised into self-management versus routine care, with thromboembolic and haemorrhagic complications as primary outcomes (unpublished data, P. T. Sawicki and A. Siebenhofer) .
As shown by the results of our studies, and according to the recommendation of Ansell (36)), successful patient selfmanagement has to include special patient training and therapy management by qualified individuals.
In conclusion, it can be said at this time, that patients' selfmanagement can improve the quality of oral anticoagulation. This is reflected by an increased number of international normalised ratio values within the target range as an indirect parameter of a reduced risk of thromboembolic and bleeding complications. Self-management of oral anticoagulation is safe, and improves treatment-related quality of life. No prospective, controlled randomised study has, as of yet, convincingly demonstrated the effect of this anticoagulation treatment on "hard endpoints", such as thromboembolic and bleeding complications.
